Terence A. Kelly
Vorstandsvorsitzender bei Perception Neuroscience Holdings, Inc.
Profil
Terence A.
Kelly is the founder of Kelly Pharma Research Consulting LLC.
He is currently the Chief Executive Officer of Perception Neuroscience, Inc. and the President & Chief Executive Officer of Perception Neuroscience Holdings, Inc. He previously served as the President & Chief Executive Officer of CoMentis, Inc. from 2011 to 2017.
Additionally, he was a Vice President at Boehringer Ingelheim Corp.
from 1990 to 2009.
He also served as an Independent Director at Cardax, Inc. from 2014 to 2021 and as a Director at Cardax Pharmaceuticals, Inc. Furthermore, he holds a doctorate from The University of Texas at Austin, an undergraduate degree from Rensselaer Polytechnic Institute, and an MBA degree from The Leonard N Stern School of Business.
Aktive Positionen von Terence A. Kelly
| Unternehmen | Position | Beginn |
|---|---|---|
| Perception Neuroscience Holdings, Inc. | Vorstandsvorsitzender | 01.11.2019 |
Perception Neuroscience, Inc.
 Perception Neuroscience, Inc. Medical/Nursing ServicesHealth Services Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Terence A. Kelly
| Unternehmen | Position | Ende |
|---|---|---|
| CARDAX, INC. | Direktor/Vorstandsmitglied | 01.08.2021 |
CoMentis, Inc.
 CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Vorstandsvorsitzender | 01.01.2017 |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | 01.01.2009 |
| Kelly Pharma Research Consulting LLC | Gründer | - |
Cardax Pharmaceuticals, Inc.
 Cardax Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cardax Pharmaceuticals, Inc. develops proprietary small molecule therapies for large unmet medical needs. It develops proprietary small molecule therapies for large unmet needs where oxidative stress and inflammation play important causative roles-including cardiovascular disease, hepatitis, macular degeneration and many cancers. The company's proprietary, synthetic, natural compound derivatives represent a novel treatment approach that offers efficacy along with an outstanding safety profile, oral bioavailability and tissue selectivity. Cardax Pharmaceuticals was founded by David G. Watumull and Samuelf Lockwood in May 2006 and is headquartered in Honolulu, HI. | Direktor/Vorstandsmitglied | - |
Ausbildung von Terence A. Kelly
| The University of Texas at Austin | Doctorate Degree |
| Rensselaer Polytechnic Institute | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CARDAX, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
CoMentis, Inc.
CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Cardax Pharmaceuticals, Inc.
Cardax Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cardax Pharmaceuticals, Inc. develops proprietary small molecule therapies for large unmet medical needs. It develops proprietary small molecule therapies for large unmet needs where oxidative stress and inflammation play important causative roles-including cardiovascular disease, hepatitis, macular degeneration and many cancers. The company's proprietary, synthetic, natural compound derivatives represent a novel treatment approach that offers efficacy along with an outstanding safety profile, oral bioavailability and tissue selectivity. Cardax Pharmaceuticals was founded by David G. Watumull and Samuelf Lockwood in May 2006 and is headquartered in Honolulu, HI. | Health Technology |
| Kelly Pharma Research Consulting LLC | |
Perception Neuroscience, Inc.
Perception Neuroscience, Inc. Medical/Nursing ServicesHealth Services Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY. | Health Services |
| Perception Neuroscience Holdings, Inc. |
